Quinton-Scribner arteriovenous shunts for hemodialysis. A review of 6.5 years' experience.
Quinton-Scribner shunts have been used as a reliable access to the blood-stream in 56 patients treated with intermittent hemodialysis in the years 1965-71. The mean age of 29 men and 27 women was 39 years. Two hundred and thirty-two cannulae showed a mean survival time of 11.2 months for 103 arterial cannulae and 9.0 months for 129 venous cannulae. 700 shunt clotting episodes occurred during 1157 patient months, i.e. 0.6 clotting episode/month. In 350 episodes where saline flushing could not remove the clot, the effect of treatment with streptokinase was considered evident in 79.7%. Shunt cannula infection was a common complication while aseptic cutaneous necrosis and bleeding from the cannulated vessel were seen less frequently. Both severe and less harmful bleeding episodes were seen as a complication of dicumarol therapy. The number of complications to streptokinase treatments was low. The advantages and disadvantages of the Quinton-Scribner shunt for hemodialysis are discussed.
D000293:Adolescent; D000328:Adult; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects / Q000451:nursing; D001777:Blood Coagulation / Q000187:drug effects; D002648:Child; D001728:Dicumarol / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D005334:Fever / Q000209:etiology; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010020:Osteonecrosis / Q000209:etiology; D011183:Postoperative Complications; D006435:Renal Dialysis; D012965:Sodium Chloride / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000209:etiology; D013300:Streptokinase / Q000009:adverse effects / Q000494:pharmacology; D013530:Surgical Wound Infection
D012965:Sodium Chloride; D001728:Dicumarol; D013300:Streptokinase